Protein / target
Interleukin-4 receptor subunit alpha
Protein at a glance
Biological role
Interleukin-4 receptor
Strongest disease association
Asthma
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Receptor for both interleukin 4 and interleukin 13.
View complete UniProt function annotationHide complete annotation
Receptor for both interleukin 4 and interleukin 13 (PubMed:17030238). Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2
Subcellular location
Domains and Gene Ontology detail (17)Hide
Domains & features
Gene Ontology
- Cexternal side of plasma membrane
- Cextracellular region
- Cplasma membrane
- Creceptor complex
- Finterleukin-4 receptor activity
- Pcell surface receptor signaling pathway via JAK-STAT
- Pimmune response
- Pinterleukin-13-mediated signaling pathway
- Pinterleukin-4-mediated signaling pathway
- Ppositive regulation of chemokine production
- Ppositive regulation of cold-induced thermogenesis
- Ppositive regulation of leukocyte differentiation
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·Receptor for both interleukin 4 and interleukin 13 (PubMed:17030238). Couples to the JAK…
- ·interleukin-4 receptor activity
- ·immune response
- ·interleukin-13-mediated signaling pathway
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Interleukin-4 receptor subunit alpha antagonist
Indicated for Asthma, Dermatitis, Atopic, Eczema, Nasal Polyps
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene IL4R
Gene-level evidence surfaced through the gene IL4Rthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
2 compounds recorded · 1 approved · 1 in clinical development
View all recorded compounds (2)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Antibodies — Strong
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (7)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: DUPILUMAB (BLA761055)
- Indication expanded
Indication expansion: DUPILUMAB (BLA761055)
- Label change
Label change: DUPILUMAB (BLA761055)
- Indication expanded
Indication expansion: DUPILUMAB (BLA761055)
- Indication expanded
Indication expansion: DUPILUMAB (BLA761055)
- Indication expanded
Indication expansion: DUPILUMAB (BLA761055)
- Label change
Label change: DUPILUMAB (BLA761055)
- Safety communication
Drug Safety Update: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- New publicationDupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
- New publicationTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
- New publicationDupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
- New publicationDupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.